The cures …
A Big Pharma report on cancer treatments in the pipeline (not a medical article but propaganda; a good summary nonetheless):
https://www.phrma.org/report/medicines-in-development-for-cancer-2018-report
Medicines in Development for Cancer 2018 Report
Excerpts (minus citations) shown below from full 6-page report. Download report at:
http://phrma-docs.phrma.org/files/dmfile/2018_MID_Cancer.pdf
More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
In recent decades, substantial progress has been made in the fight against cancer. Since peaking in the 1990s, cancer death rates have declined 26 percent, leading to more than 2.3 million cancer deaths avoided. Accordingly, rates of cancer survivorship continue to rise. The number of cancer survivors living in the United States has increased from three million in 1971 to 15.5 million as of January 1, 2016. Approximately 73 percent of survival gains in cancer are attributable to new medicines. Between 1988 and 2000, treatment advances in cancer have saved 23 million years of life and added $1.9 trillion to society based on improved productivity, extended life and other factors. And, since 1975, the chances that a cancer patient will live five years or more have increased by 41 percent across all cancers. …
Today, 1,120 medicines and vaccines for cancer are currently in development by America’s biopharmaceutical companies, all of which are in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA). The medicines in development include:
• 137 for several types of leukemia, which accounts for more than three percent of all new cases of cancer.
• 135 for lymphoma, including non-Hodgkin lymphoma, which accounts for nearly five percent of all new cancer diagnoses.
• 132 for lung cancer, the leading cause of cancer death in the United States, with more than 154,000 deaths and 234,030 new cases expected in 2018.
• 108 for breast cancer, the leading cancer diagnosed in women in the United States with more than 266,000 new cases expected in 2018.
• 90 for brain tumors, including gliomas, which represent nearly 25 percent of all primary brain tumors.
• 46 for skin cancer, including melanoma, which accounts for 69 percent of all skin cancer deaths (excluding basal and squamous cell).
Other medicines in development target colorectal cancer, prostate cancer, ovarian cancer, childhood cancers and solid tumors, among others.